简介:目的研究c—erbB—2和c—myc癌基因在胃癌组织中扩增的意义。方法应用非放射性原位杂交技术检测81例胃癌标本中c—erbB—2和c—myc的扩增情况。结果C—erbB—2和c—myc在胃癌中的扩增率分别为50.6%和67.9%。c—erbB—2基因与胃癌组织分化程度、浸润深度及淋巴结转移有关(P〈0.05),分化程度越差、浸润深度越深、淋巴结有转移,c—erbB—2基因表达率越高,而C—myc癌基因与胃癌组织分化程度、浸润深度及淋巴结转移无关。两基因的扩增具有显著的相关性(x^2=7.26,P〈0.01)。结论c—erbB—2和c—myc扩增是胃癌发生过程中的一个重要的生物学因素,且两者具有较好的协同作用。
简介:目的探讨色素内镜对上消化道早期癌及癌前病变的诊断价值。方法内镜下对98例可疑病变进行黏膜染色,分别在染色前后进行内镜诊断比较,并与活检或手术切除灶的病理结果分析对比。结果食管黏膜染色36例,不着色区取材6例,病理报告鳞癌5例,腺癌1例,浅着色区取材30例,病理报告食管炎症12例,轻度不典型增生7例.中度不典型增生6例,重度不典型增生3例,鳞癌2例,浅着色区不典型增生诊断率为53.3%,染色前后食管癌诊断符合率分别为50%和75%,比较病理诊断,染色后诊断符合率提高25%。胃黏膜染色62例,病理诊断胃溃疡26例,伴异型增生10例,胃黏膜内癌18例,胃黏膜下癌15例,染色前后早期癌诊断分别为75.8%和87.9%,比较病理诊断,染色后诊断符合率提高12.1%。结论色素内镜可提高病变活检准确率及上消化道早期癌及癌前病变的诊断率,方法简便安全,值得基层医院推广。
简介:目的掌握影响肝性脑病(HE)预后的危险因素。方法对国内发表资料完整、统计设计合理的11个HE研究(共1131例)进行荟萃分析。结果HE诱因分别为:消化道出血43.8%,感染33.9%,电解质紊乱29.1%,大量利尿和/或放腹水14.5%,饮食不节14.2%,肾功能衰竭13.0%,手术/创伤6.0%,药物4.5%,输血/输复合氨基酸3.2%,腹泻2.4%,便秘1.8%,原因未明/无2.7%.与HE死亡率相关因素包括:①诱因数:单一诱因死亡率33%,二种诱因为71.4%;三种或以上诱因为92.3%;三组间差异显著(P〈0.01)。②诱因纠正情况:可纠正组死亡率为18.2%,未纠正组为100%,二组间差异显著(P〈0.01)。③HE分期:Ⅰ期死亡率为O%,Ⅱ期为4.9%.Ⅲ期为34.4%,Ⅳ期为85.1%,四组间差异显著(P〈0.01)。④肝功(Child—pugh分级):A级死亡率为19.8%,B级为49.8%,C级为80.8%,三组间差异显著(P〈0.01)。结论重视HE预后的危险因素,警惕多种诱因并存,消除其不利影响。保护肝功能是改善HE预后的重要途径。
简介:AIMToinvestigatetheroleofthecomplement5a(C5a)/C5areceptor(C5aR)pathwayinthepathogenesisofacuteliverfailure(ALF)inamousemodel.METHODSBALB/cmicewererandomlyassignedtodifferentgroups,andintraperitonealinjectionsoflipopolysaccharide(LPS)/D-galactosamine(D-GalN)(600mg/kgand10μg/kg)wereusedtoinduceALF.TheKaplanMeiermethodwasusedforsurvivalanalysis.Serumalanineaminotransferase(ALT)levels,atdifferenttimepointswithina1-wkperiod,weredetectedwithabiochemistryanalyzer.Pathologicalexaminationoflivertissuewasperformed36hafterALFinduction.Serumcomplement5(C5),C5a,tumornecrosisfactor-α(TNF-α),interleukin(IL)-1β,IL-6,high-mobilitygroupproteinB1(HMGB1)andsphingosine-1-phosphatelevelsweredetectedbyenzyme-linkedimmunosorbantassay.Hepaticmorphologicalchangesat36hafterALFinductionwereassessedbyhematoxylinandeosinstaining.ExpressionofC5aR,sphingosinekinase1(SphK1),p38-MAPKandp-p38-MAPKinlivertissue,peripheralbloodmononuclearcells(PBMCs)andperitonealexudativemacrophages(PEMs)ofmiceorRAW264.7cellswasanalyzedbywesternblotting.C5aRmRNAlevelsweredetectedbyquantitativereal-timePCR.RESULTSActivationofC5andup-regulationofC5aRwereobservedinlivertissueandPBMCsofmicewithALF.BlockadeofC5aRwithaC5aRantagonist(C5aRaC5aRa)significantlyreducedthelevelsofserumALT,inflammatorycytokines(TNF-α,IL-1βandIL-6)andHMGB1,aswellasthelivertissuedamage,butincreasedthesurvivalrates(P<0.01forall).BlockadeofC5aRdecreasedSphK1expressioninbothlivertissueandPBMCssignificantlyat0.5hafterALFinduction.C5aRapretreatmentsignificantlydownregulatedthephosphorylationofp38-MAPKinlivertissuesofALFmiceandC5astimulatedPEMsorRAW264.7cells.Moreover,inhibitionofp38-MAPKactivitywithSB203580reducedSphK1proteinproductionsignificantlyinPEMsafterC5astimulation.CONCLUSIONTheC5a/C5aRpath
简介:目的观察端粒酶催化亚基(hTERT)、c-myc在胆囊癌中的表达,探讨hTERT及c-myc与胆囊癌的相关性。方法采用免疫组织化学方法检测15例胆囊癌组织、癌旁组织、正常胆囊黏膜及20例胆囊腺瘤性息肉组织hTERT、c-myc的表达。结果①正常胆囊黏膜、胆囊腺瘤性息肉组织、癌旁组织及胆囊癌组织hTERT的阳性表达率分别为6,67%(1/15)、10.00%(2/20)、33.33%(5/15)及80%(12/15);c-myc阳性表达率分别为20.00%(3/15)、45.00%(9/20)、40%(6/15)及86.67%(13/15);胆囊癌组织中hTERT与c-myc阳性表达率明显高于其它组织(P〈0.05);②胆囊癌组织hTERT和c-myc表达与淋巴结转移有关,伴淋巴结转移的胆囊癌hTERT及c-myc阳性表达率明显高于无淋巴结转移者(P〈0.05);③c-myc在hTERT阳性的胆囊癌组织的表达率明显高于hTERT阴性组(P〈0.05)。结论hTERT过度表达在胆囊癌的发生发展过程中具有重要作用,c-myc在转录水平上调控hTERT的表达,进而激活端粒酶促进胆囊癌的形成。
简介:背景:临床上评估炎症性肠病活动性的方法有临床活动度、C反应蛋白(CRP)和血沉等,三者常不一致。目的:探讨CRP评估炎症性肠病活动性的价值。方法:以Logistic回归法分析80例克罗恩病(CD)、70例溃疡性结肠炎(UC)患者血清CRP与血沉、临床活动度、内镜表现活动性、组织学活动性、低白蛋白血症、贫血、白细胞升高的关系;比较临床严重度、病变部位和药物治疗对CRP的影响。结果:CD中CRP与血沉相关;UC中CRP与血沉、外周血白细胞升高相关。CRP在活动性CD中显著升高(P〈0.01),重度CD和结肠CD中CRP升高较其他各组明显(P〈0.05);活动性UC中CRP亦显著升高(P〈0.01),重度组中CRP升高较其他组明显(P〈0.05)。药物有效控制临床表现时.CRP显著下降(P〈0.01),复发时重新升高(P〉0.05)。结论:CRP升高更适于反映中至重度结肠CD和UC的活动性:具有快速反映药物治疗有效性的特点。
简介:AIM:Toevaluatetheimpactofsociodemographic/clinicalfactorsonearlyvirologicalresponse(EVR)topegin-terferon/ribavirinforchronichepatitisC(CHC)inclinicalpractice.METHODS:Weconductedamulticenter,cross-sectional,observationalstudyinHepatologyUnitsof91Spanishhospitals.CHCpatientstreatedwithpeginterferonα-2aplusribavirinwereincluded.EVRwasdefinedasundetectablehepatitisCvirus(HCV)-ribonucleicacid(RNA)or≥2logHCV-RNAdecreaseafter12wkoftreatment.AbivariateanalysisofsociodemographicandclinicalvariablesassociatedwithEVRwascarriedout.IndependentfactorsassociatedwithanEVRwereanalyzedusingamultipleregressionanalysisthatincludedthefollowingbaselinedemographicandclinicalvariables:age(≤40yearsvs>40years),gender,race,educationallevel,maritalstatusandfamilystatus,weight,alcoholandtobaccoconsumption,sourceofHCVinfection,alanineaminotransferase(ALT)andaspartateaminotransferase(AST)levels,andgammaglutamyltranspeptidase(GGT)(≤85IU/mLvs>85IU/mL),serumferritin,serumHCV-RNAconcentration(<400000vs≥400000),genotype(1/4vs3/4),cirrhoticstatusandribavirindose(800/1000/1200mg/d).RESULTS:Atotalof1014patientswereincludedinthestudy.Meanageofthepatientswas44.3±9.8years,70%weremale,and97%wereCaucasian.ThemainsourcesofHCVinfectionwereintravenousdrugabuse(25%)andbloodtransfusion(23%).SeventyeightpercentwereinfectedwithHCVgenotype1/4(68%hadgenotype1)and22%withgenotypes2/3.TheHCV-RNAlevelwas>400000IU/mLin74%ofpatients.ThemeanALTandASTlevelswere88.4±69.7IU/mLand73.9±64.4IU/mL,respectively,andmeanGGTlevelwas82±91.6IU/mL.Themeanferritinlevelwas266±284.8μg/L.Only6.2%ofpatientspresentedwithcirrhosis.Allpatientsreceived180mgofpeginterferonα-2a.Themostfrequentlyusedribavirindoseswere1000mg/d(41%)and1200mg/d(41%).Theplannedtreatm
简介:瞄准:为了在病人调查胰岛素抵抗和糖尿病的临床的参数的流行,由长期的丙肝(CHC)或长期的肝炎B(CHB)影响了。方法:我们回顾地评估了经历了肝活体检视的852个连续病人(726CHC和126CHB)。我们记录了年龄,性别,中高音,类型2糖尿病或新陈代谢的症候群(MS),身体团索引(BMI),和明显的疾病持续时间(增加)。结果:年龄,增加,BMI,在有温和/中等的肝纤维变性的病人的MS和糖尿病的流行在CHC是显著地更高的。然而,脂肪变性的度和在肝活体检视评估的肝纤维变性没在CHC和CHB病人之间不同。在多变量分析,年龄,性别,BMI,中高音和糖尿病是为在CHC的肝纤维变性的独立风险因素,而仅仅年龄与在CHB的肝纤维变性有关。我们也评估了在重要脂肪变性之间的协会(>30%)并且年龄,性别,BMI,糖尿病,MS和肝纤维变性。糖尿病,BMI和肝纤维变性与脂肪变性>被联系30%在CHC,而仅仅年龄和BMI与在CHB的脂肪变性有关。结论:这些数据可以显示丙肝病毒感染是为胰岛素抵抗的一个风险因素。
简介:瞄准:估计临床,生物化学并且virological在长期的丙肝(CHC)的长期的结果有在加ribavirin的peginterferon(PEG-IFN)以后的持续virological回答(SVR)的病人联合治疗。方法:有在有PEG-IFN正ribavirin的治疗以后的SVR的一百和53个病人在一个单个西班牙的中心在5年的后续研究被包括,基于标准临床的实践。临床的回忆,生物化学的分析,丙肝病毒RNA和alpha-fetoprotein测量,ultrasonography和短暂elastography每年被执行。结果:153个病人的吝啬的后续经期是76??敦瑥吗?
简介:AIM:ToinvestigatehowweightgainafterOLTaffectsthespeedoffibrosisprogression(SFP)duringrecurrenthepatitisCvirus(HCV)infectionofthegraft.METHODS:Ninetyconsecutivepatients(63males,medianage53years;55withHCV-relatedliverdisease),transplantedatasingleinstitution,werestudied.Allwerefollowedforatleast2yearsafterOLTandhadatleastonefollow-upgraftbiopsy,performednotearlierthan1yearafterthetransplantoperation.Foreachbiopsy,asingle,experiencedpathologistgaveanestimateofboththestagingaccordingtoIshakandthedegreeofhepaticsteatosis.TheSFPwasquantifiedinfibrosisunits/month(FU/mo).Thelipidmetabolismstatusofpatientswassummarizedbytheplasmatriglycerides/cholesterol(T/C)ratio.Bodymassindex(BMI)wasmeasuredbeforeOLT,and1and2yearsafterit.RESULTS:IntheHCVpositivegroup,thehighestSFPwasobservedinthefirstpost-OLTyear.Atthattimepoint,aSFP≤0.100FU/mowasobservedmorefrequentlyamongrecipientswhohadreceivedtheirgraftfromayoungdonorandhadapre-transplantBMIvalue>26.0kg/m2.Atcompletionofthefirstpost-transplantyear,aBMIvalue>26.5kg/m2wasassociatedwithaT/Cratio≤1.TheproportionofpatientswithSFP>0.100FU/modescendedinthefollowingorder:femalerecipientswithahighT/Cratio,malerecipientswithhighT/Cratio,andrecipientsofeithergenderwithlowT/Cratio.Hepaticsteatosiswasobservedmorefrequentlyinrecipientswho,inthefirstpost-transplantyear,hadincreasedtheirBMI≥1.5kg/m2incomparisontothepre-transplantvalue.Hepaticsteatosiswasinverselyassociatedwiththestagingscore.CONCLUSION:AmongHCVpositiverecipients,excessweightgainpost-OLTdoesnotrepresentafactorfavoringearlyliverfibrosisdevelopmentandmightevenbeprotectiveagainstit.
简介:AIM:Tocomparetwotypesofclassificationofintestinalmetaplasia(IM)ofthestomachandtoexploretheirrelationshiptogastriccarcinoma.METHODS:Forty-sevencasesofgastricIMwereclassifiedintotypeortypeaccordingtomucinhistochemicalstainingandcomparedwithanovelclassificationinwhichthespecimenswereclassifiedintosimpleIM(SIM)oratypicalIMaccordingtopolymorphismintermsofatypicalchangesofthemetaplasticepithelium.Forty-sevenIMandthirty-sevengastriccarcinomasa...
简介:目的建立c-Met慢病毒载体转染人脐带间充质干细胞(hUMSC),为治疗肝衰竭作为种子细胞.方法培养hUMSC,经流式细胞技术检测细胞表面表型,转染c-Met慢病毒载体,在荧光显微镜下观察转染效率,确定最佳多重感染复数(MOI).采用嘌呤霉素抗性筛选稳定表达c-Met的hUMSC细胞系,采用Western-blot法检测细胞c-met蛋白表达量.结果P5代细胞高表达CD44、CD90和CD105抗原,不表达CD31、CD45和CD34相关造血细胞抗原,符合人脐带间充质干细胞的特性;构建成功的c-Met慢病毒载体转染人脐带间充质干细胞最佳MOI=80,经嘌呤霉素筛药,在荧光显微镜下观察发现荧光阳性率为100%,且经Western-blot法检测证实该细胞过表达c-Met蛋白.结论成功构建过表达c-Met基因的脐带间充质干细胞,为进-步实验打下了基础.